Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04766177

Role of Bumetanide in Treatment of Autism

Role of bumetanide in Autism

Recruiting

Interested in participating?

Request Info

Key information

Age range

3 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

About this study

Role of Bumetanide in Treatment of Autism spectrum disorder in children

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients with ASD diagnosed by CARS rating Scale⩾30.
  • Age of patients range between (3-12) years.

Exclusion criteria

  • Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).

Treatment and study plan

Bumetanide

Drug

bumetanide 0.5 mg twice daily

Other names: burinex

Placebo

Drug

placebo tablets twice daily

Other names: Placebo treatment

Primary outcomes

  1. Number of patients with improved CARS score

    Time frame: 6 months

    the patients with improved CARS score

Study contacts

Contact information is provided by the study sponsor or research team.

Sherief Abd-Elsalam, ass. prof.

CONTACT

[email protected]

00201147773440

Sponsors and collaborators

Lead sponsor

Sherief Abd-Elsalam

Other

Registry information

Official study title

Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children

Important dates

Study start
2021
Primary completion
2030
Study completion
2030
First posted
Feb 23, 2021
Registry last updated
Feb 23, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.